AI-Powered Growth & Sales Acceleration Program

AI-Powered Growth & Sales Acceleration Program
Genostim Performance Labs · Prepared by the Pet Jet LLC Advisory Consortium
Confidential · April 2026
Client Proposal
Advisory Consortium
Four Firms. One Aligned Mission.
Pet Jet LLC
Pet industry, veterinary distribution, brand strategy, DTC operations
Scale Foundry
Supply chain, fulfillment, D2C platform architecture, operational scaling
TIN
Custom AI tooling, SEO automation, content at scale, digital marketing
Velocity Partners
Financial modeling, investor relations, co-investment, CFO advisory
Proposal at a Glance
$8.86B
Total Addressable Market
818×
Digital Gap to Close
$110M
Year-5 Revenue Target
15–20%
Equity Engagement Model
Executive Summary
A Scientifically Differentiated Platform
The Science
Genostim's proprietary Isotide™/Hexatide™ Complex delivers 18 bioactive amino acids and 21 natural growth factors via pinocytosis — a 'cell drinking' mechanism enabling intact peptide delivery directly into the bloodstream, bypassing enzymatic degradation that limits conventional supplements.
The Problem
The product is not the issue. Genostim's combined digital footprint is valued at just $275/month in organic traffic — an 818× deficit vs. benchmark competitor BodyBio ($224,911/month) and 6,000× behind category leaders Thorne and Garden of Life. This is a recoverable commercial opportunity.
The Engagement Model
The Pet Jet LLC Advisory Consortium proposes an Advisory for Equity engagement: the full suite of advisory, implementation, digital infrastructure, distribution, and financial services — in exchange for a 15–20% equity stake in Genostim Performance Labs. The consortium co-invests alongside Genostim and assists in sourcing the initial $500K–$2M financing required to fund the commercial build-out. No commission. Aligned incentives. Shared upside.
Market Opportunity
Two Secular Growth Markets
US Peptide Supplement Market
Reached $717M in 2023, growing at ~18% CAGR — driven by biohacking, longevity medicine, sports science, and mainstream awareness of growth factor biology.
US Pet Supplement Market
Hit $4.76B in 2025, growing at ~10% CAGR — driven by pet humanization and premiumization of companion animal nutrition. Chewy autoship represents 82% of net sales (Q3 2024).
The dual human/pet platform is a structural competitive advantage. No competitor in the peptide space has a credible, science-backed companion animal line. TGFL is a category creation opportunity.
TAM · SAM · SOM
Even at conservative 0.1% SAM penetration in Year 1, Genostim generates $3.1M in revenue — sufficient to establish proof of concept and attract follow-on financing.
Revenue Scenarios
0.1% to 3% SAM Penetration
Revenue scales from $3.2M (0.1% SAM, Year 1) to $96M (3.0% SAM, Year 5) as the full channel architecture is activated across DTC, retail, veterinary, and international markets.
Revenue Scenarios — Detail
Financial Model
36-Month Cash Flow Projection
Revenue ramps from $27K/month (Month 1) to ~$400K/month by Month 36. Cumulative breakeven is projected at Month 14–16 on the base case.
Financial Model — Key Assumptions
Initial Investment
$500,000 — co-investment supported by consortium; revenue-based financing option available. Funds first 6 months of operations.
Gross Margin
55% — manufacturing, cold-chain packaging, and fulfillment of the Isotide™/Hexatide™ Complex. Consistent with premium DTC supplement brands.
Marketing Spend
~35% of revenue in Year 1, declining to 18% by Year 3 as organic and referral efficiency compounds.
Fixed OpEx
$80K/month — team, technology infrastructure, and overhead. Advisory for Equity model eliminates upfront fee cash outflows.
The Science Platform
Isotide™/Hexatide™ Complex
The scientific foundation is documented in the 7-volume Peptide Effect series by Lauriston Crockett III — more than 20 years of research into bioactive peptide delivery, growth factor biology, and cellular regeneration. This body of work constitutes a meaningful intellectual property asset and underpins both the Genostim® human line and The Gift for Life® companion animal line.
The Pinocytosis Advantage
The Problem with Conventional Supplements
Digestive enzymes in the stomach and small intestine degrade most bioactive peptides before absorption — rendering conventional oral peptide supplements largely ineffective at the cellular level.
Genostim's Solution: Pinocytosis
Pinocytosis — literally 'cell drinking' — is a natural endocytic mechanism in which intestinal epithelial cells engulf intact peptide molecules. This enables bioactive peptides to cross the gut wall intact and enter the bloodstream, reaching target tissues throughout the body.
18 Amino Acids + 21 Growth Factors
The Isotide™/Hexatide™ Complex contains all 18 essential and conditionally essential amino acids plus a proprietary blend of 21 natural growth factors:
GF-1 / GF-2
Insulin-like Growth Factors — muscle protein synthesis, cellular repair
TGF-B
Transforming Growth Factor Beta — tissue remodeling, immune regulation
EGF
Epidermal Growth Factor — skin cell proliferation, epithelial tissue repair
NGF
Nerve Growth Factor — neuronal survival, cognitive function support
GHK-Cu
Copper Peptide — collagen and elastin stimulation, antioxidant activity
FGF + CHDP
Angiogenesis, muscle repair, joint health, proteoglycan synthesis
Plus TNF-A, TNF-B, CTGF, and 11 additional bioactive growth factors supporting systemic cellular homeostasis.
10 Benefit Pillars
Muscle Recovery & Athletic Performance
Accelerated repair, reduced DOMS, improved VO2 adaptation
Cognitive Function
NGF-mediated neuroprotection; mood stability, focus, memory consolidation
Immune Modulation
TNF-mediated adaptive immunity; reduced inflammatory cytokine burden
Joint Health & Mobility
CHDP and CTGF support cartilage preservation and synovial fluid quality
Cardiovascular Health
FGF-mediated angiogenesis; endothelial health support
Longevity & Cellular Regeneration
Systemic growth factor support for tissue homeostasis
Additional Benefit Pillars
Skin, Hair & Nail Integrity
EGF + GHK-Cu drive collagen turnover and dermal thickness
Hormonal Balance
GF-1/GF-2 insulin sensitivity; adrenal axis regulation
Gut Health & Digestion
Mucosal repair, tight junction integrity
Energy & Mitochondrial Health
Amino acid substrate optimization for ATP synthesis
Genostim® serves the human market. The Gift for Life® (TGFL) applies the same science platform to companion animals — a category creation opportunity with no credible science-backed competitor.
Digital Strategy
Closing the 818× Digital Gap
Genostim's organic traffic value is approximately $275/month vs. BodyBio's $224,911/month — an 818× deficit. The Information Network (TIN) brings custom AI tooling trained on Genostim's proprietary science library, Crockett's Peptide Effect series, and competitive keyword data to produce a content engine generating topical authority across peptide, anti-aging, cellular health, and pet wellness categories.
AI-Powered Content & SEO Engine — Phase 1
Months 1–3 · Foundation
01
Technical SEO Audit
Core Web Vitals, schema markup, canonical structure remediation
02
Keyword Architecture
500+ target keywords mapped to content clusters across 10 benefit pillars
03
Content Brief Library
200 AI-generated long-form article briefs; e-commerce UX rebuild for DTC checkout
04
Brand Identity Refresh
Unified visual system across Genostim + TGFL product lines
AI-Powered Content & SEO Engine — Phase 2
Months 4–9 · Authority Building
100 Long-Form SEO Articles
1,500–3,000 words each, fully optimized for target keyword clusters
Practitioner Education Portal
Veterinary CE module library and physician resource center
YouTube Content Series
'The Peptide Effect' — 24 episodes based on Crockett research
Email List & Affiliate Launch
50,000 engaged subscribers via lead magnet + quiz funnel; 200 affiliate partnerships on ShareASale/Impact
AI-Powered Content & SEO Engine — Phase 3
Months 10–18 · Scale & Monetize
500+ Published Articles
Estimated 50,000+ monthly organic visits by Month 18
Amazon FBA
Subscribe & Save activation across top 5 SKUs
Paid Media
Meta + Google, $20–30K/month spend, target 3:1 ROAS
Influencer Network
50 micro-influencers in sports recovery, pet health, and biohacking niches; PR in longevity and pet trade press
Distribution Strategy
Channel Architecture Overview
Five channels activate sequentially — DTC first for speed and margin, then affiliate, veterinary, national retail, and international — each building on the prior channel's subscriber base and brand authority.
Direct-to-Consumer / E-Commerce
DTC is the highest-margin channel (~70–75% gross margin after fulfillment) and the fastest to activate. Priority platforms: brand website (Shopify), Amazon FBA, and Subscribe & Save autoship. Autoship programs in the supplement category achieve 80%+ retention at 12 months when anchored to a compelling science narrative. Year 1 DTC target: $1.2M.
Affiliate, Influencer & Veterinary Channels
Affiliate & Influencer
Biohacking, longevity, and pet wellness communities are natural affiliate ecosystems. Key platforms: ShareASale, Impact, CJ Affiliate. Benchmark commission: 15–20% recurring. Micro-influencer strategy targets 50K–500K follower accounts in sports recovery, anti-aging, and pet health.
Year 1 target: $0.8M
Veterinary & Pet Specialty Retail
Highest average order value and most defensible customer relationship. Key distributors: MWI Animal Health, Patterson Veterinary, Covetrus. Specialty retail: Natural Grocers, Whole Foods, Vitamin Shoppe. Pet specialty: Pet Supplies Plus (1,500+ stores).
Year 1 vet + pet retail target: $0.5M
National Retail & International Expansion
1
Year 2 — National Retail
GNC (2,200 US stores), Vitamin Shoppe, Natural Grocers no-fee program, functional fitness gyms, CrossFit affiliates. Target: $1.5M
2
Year 3 — International Export
GRAS designation simplifies import compliance in EU, Canada, Australia, and Asian markets. One preferred distributor per major geography. Target: $3.5M
Average annual subscriber value: $480–$840/household for dual human + pet autoship. No competitor in the peptide space has a credible companion animal line.
The Consortium
Four Specialized Firms. Complete Coverage.
Advisory for Equity
Value Creation Model
The consortium provides its full service suite — advisory, implementation, technology, distribution, and financial support — in exchange for a 15–20% equity stake in Genostim Performance Labs. This eliminates upfront fee obligations for Genostim while aligning the consortium's incentives directly with commercial outcomes. Valuation is modeled at a conservative 3× revenue multiple.
Equity Value Projection
At Year 5 stretch revenue of $110M, company valuation reaches $330M. A 20% equity stake is then worth $66M — a return that justifies the consortium's full service commitment and co-investment.
Advisory for Equity — Structural Terms
Equity Stake
15–20% structured as restricted units; 3-year vesting, 1-year cliff
Services Rendered
Full advisory, implementation, AI/tech, distribution, financial, and content services
Co-Investment
Consortium identifies and syndicates $500K–$2M initial financing; Genostim contributes product supply and founder IP
Governance
Board observer seat; quarterly OKRs; tag-along and drag-along rights above agreed valuation threshold
Go-To-Market Roadmap
Five Phases to Category Leadership
1
Foundation
Q1–Q2 2026 · Brand refresh, DTC launch, SEO, affiliate seed · $0.3M
2
Traction
Q3–Q4 2026 · Influencer, vet pilot, Amazon FBA, autoship · $2.8M
3
Scale
2027 · National retail, subscriber growth, content authority · $14.6M
4
Expansion
2028 · International, brand extensions, channel acquisitions · $38M
5
Leadership
2029–2030 · Category leadership, platform licensing, exit · $72–110M
Market Growth Trajectory 2022–2033
The combined TAM is projected to reach approximately $11.3B by 2033. Genostim's April 2026 entry is early enough to build category authority before venture-backed competitors arrive, yet late enough that consumer demand is established. Timing is a competitive asset.
Why Now? A Structurally Advantageous Moment
Peptide Market Inflection
Consumer awareness of 'peptide therapies' tripled between 2021 and 2024 as the biohacking community mainstreamed growth factor concepts previously confined to clinical settings.
Pet Market Generational Shift
Millennial and Gen Z pet owners spend 40% more per pet than prior generations and treat companion animal health as co-equal to their own — driving premiumization across the pet supplement category.
Engagement Terms
Proposed Engagement Structure
Next Steps
The Pet Jet LLC Advisory Consortium is ready to begin work immediately upon execution of a term sheet. Each step builds toward a fully aligned, equity-based partnership with shared upside and no upfront fees.
What Genostim Provides
To begin the due diligence process, Genostim is asked to provide:
1
Financial Statements
P&L, balance sheet, and current cash position
2
Customer & Subscriber Database
Size, lifetime value, and acquisition channel summary
3
Product COGS Detail
Manufacturing partner information and unit economics
4
IP Inventory
Trademarks, pending patents, and licensing agreements
5
Distribution Agreements
Existing channel partnerships and distribution contracts
Ready to Build Something Exceptional
The Pet Jet LLC Advisory Consortium brings four specialized firms, aligned incentives, and a complete commercial build-out capability to Genostim Performance Labs. No upfront fees. No misaligned commissions. Pure equity partnership — built to win.
Contact
joey@mypetjet.com · mypetjet.com
Prepared
April 2026 · Pet Jet LLC Advisory Consortium
Confidential
Not for distribution without written consent